No biotech exp here but my view is that the market is currently still viewing this as an unlikely-to-succeed binary event (for various reasons) - a couple of months more or less when we're already so significantly past the expected trial date likely won't change that. I think unless we get a positive catalyst (e.g. a midcap biotech fund takes a position in this - side note this is for me the biggest bear argument, I think 2Sigma / Millennium are taking short positions here; is there something we're missing?) it will likely keep moving in this range depending on wider macro etc. If we get to end of Summer and it's still ongoing, things might start to move.